BTG
LIVE

Serial Number

77858442

Owner

BTG International Limited

Attorney

Jonathan A. Hyman

Filing Date

Oct 27, 2009

Add to watchlist:

No watchlists yet
View on USPTO

BTG Trademark

Serial Number: 77858442 • Registration: 3859364

BTG is a trademark filed by BTG International Limited on October 27, 2009. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

BTG International Limited (35 trademarks)

5 Fleet Place
London EC4M 7RD , GB

Entity Type: 11

Protherics Medicines Development Limited (20 trademarks)

London EC4M7RD , GB

Entity Type: 11

Trademark Details

Filing Date

October 27, 2009

Registration Date

October 12, 2010

Published for Opposition

July 27, 2010

Goods & Services

Pharmaceutical and medicinal preparations and substances namely, vaccines and vaccine adjuvants, proteins, peptides, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances or sepsis; pharmaceutical preparations and substances for the treatment of thrombosis, [ inflammation, autoimmune disease and sleep disorders; dietetic foods adapted for medical use; ] vaccines; sera; polyclonal antibodies and fragments thereof for in vitro disease testing and for use in treating snake envenomation, overdose of toxic substances or sepsis; pharmaceutical preparations in the form of foams or for use in producing foams for use in sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins or arteriovenous malformations; chemical reagents for medical or veterinary purposes; chemical reagents for therapeutic and diagnostic purposes, namely, for the treatment of and the diagnosis of the presence of toxic substances; pharmaceutical preparations for the treatment of cancer; [ pharmaceutical preparations for the reduction or elimination of circulating cytokines; pharmaceutical preparations for the treatment of neurodegeneration and multiple sclerosis; pharmaceutical preparations for the treatment of pain, including headache and migraine; ] pharmaceutical preparations for promoting the healing of dermal wounds and chronic wounds including ulcers and pressure sores; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical preparations for the treatment of envenomation with snake venom; pharmaceutical preparations for treatment of excess levels of cancer agents; pharmaceutical preparations for the treatment of toxic levels of other pharmaceutical agents; pharmaceutical preparations for the treatment of cytotoxic cancer treatment drug overdose, particularly overdose with methotrexate; [ pharmaceutical preparations for the treatment of sleep apnea; pharmaceutical preparations for the treatment of head lice; ] diagnostic reagents for medical use and for the determination of levels of toxic substances in blood and tissue samples in vitro

[ Chemicals used in science; chemicals for clinical research use; diagnostic reagents and substances for clinical and medical laboratory use; diagnostic reagents and substances for clinical and medical laboratory in vitro research use; polyclonal antibodies and fragments thereof for clinical research use; diagnostic reagents and substances for in vivo clinical and laboratory research use; chemical reagents for scientific research use; chemicals used in science and medicine, namely, adjuvant compositions for use in the manufacture of vaccines and antibodies and antibody fragments for use in diagnostics and assays; cell lines for use in production of whole cell derived vaccines; cell lines for use in research related to virus mediated disease ]

Surgical apparatus for the treatment of varicose veins; medical syringes; cannula needles, medical tubing for administering drugs; surgical and medical apparatus for producing and administering pharmaceutical foams; surgical or medical apparatus for producing foams for treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; devices for intravenous administration of pharmaceutical foam; diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose

[ Product research and development, namely, development of pharmaceuticals and medical devices through preclinical and clinical research in the fields of envenomation, drug overdose, chemical poisoning, venous disease, autoimmune disease, pain and inflammation and cancer therapy ]

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 14, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 14, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 14, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 14, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 14, 2025 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 13, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 13, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 13, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 16, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 16, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 16, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 16, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 16, 2023 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 12, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 12, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Apr 12, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 12, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 12, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 12, 2022 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 30, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 30, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 30, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 30, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 30, 2021 COAR
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Jun 24, 2021 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Jun 24, 2021 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Jun 24, 2021 89AG
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Jun 22, 2021 EROP
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
Jun 9, 2021 PR89
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 14, 2021 ASGN
TEAS SECTION 8 & 9 RECEIVED
Apr 9, 2021 E89R
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 29, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 29, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 29, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 29, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 29, 2020 COAR
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Oct 12, 2019 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Apr 21, 2017 NAS8
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
Apr 21, 2017 8.PR
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 21, 2017 APRE
TEAS SECTION 8 RECEIVED
Apr 5, 2017 ES8R
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 5, 2017 TCCA
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 12, 2015 REM1
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 15, 2014 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 15, 2014 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 14, 2011 TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 6, 2011 TCCA
REGISTERED-PRINCIPAL REGISTER
Oct 12, 2010 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 27, 2010 NPUB
PUBLISHED FOR OPPOSITION
Jul 27, 2010 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 22, 2010 PREV
ASSIGNED TO LIE
Jun 21, 2010 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 4, 2010 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 28, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 28, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 28, 2010 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
May 26, 2010 GPRN
PRIORITY ACTION E-MAILED
May 26, 2010 GPRA
PRIORITY ACTION WRITTEN
May 26, 2010 CPRA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 7, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 7, 2010 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 7, 2010 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 21, 2010 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 21, 2010 GNSL
SUSPENSION LETTER WRITTEN
Apr 21, 2010 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 31, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 31, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 31, 2010 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 1, 2010 GNRN
NON-FINAL ACTION E-MAILED
Feb 1, 2010 GNRT
NON-FINAL ACTION WRITTEN
Feb 1, 2010 CNRT
ASSIGNED TO EXAMINER
Feb 1, 2010 DOCK
NOTICE OF DESIGN SEARCH CODE MAILED
Oct 31, 2009 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 30, 2009 NWOS
NEW APPLICATION ENTERED
Oct 30, 2009 NWAP